![CIRRUS 6000]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.100.56.file/ga_cropped_1.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.360.203.file/ga_cropped_1.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.768.432.file/ga_cropped_1.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1024.576.file/ga_cropped_1.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1280.720.file/ga_cropped_1.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1440.810.file/ga_cropped_1.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original./ga_cropped_1.jpg"} "CIRRUS 6000")
CIRRUS OCT
Toolkit für AMD & geografische Atrophie
Moderne Technologien leiten eine neue Ära in der AMD-Behandlung und -Versorgung ein – und auch Ihre Patientinnen und Patienten können davon profitieren: Denn Advanced RPE Analysis und ZEISS AngioPlex bieten die ganze Bandbreite an Tools für die Diagnose und Behandlung von AMD und geografischer Atrophie für ZEISS CIRRUS.
Bei Personen über 60 Jahren ist die altersabhängige Makuladegeneration (AMD) die häufigste Ursache für den schweren und irreversiblen Verlust des Sehvermögens. Die Zahl der Erkrankungen steigt weltweit in besorgniserregendem Maße. Auch Ihre Patientinnen und Patienten könnten gefährdet sein. Schätzungen zufolge litten im Jahr 2020 ca. 196 Millionen Menschen an einer AMD. Bis 2040 soll diese Zahl auf 288 Millionen Menschen ansteigen. Das entspricht einem Anstieg von rund 46 %. In Zahlen bedeutet das: Möglicherweise verlieren etwa zusätzliche 92 Millionen Menschen ihre Sehkraft – ohne etwas davon zu ahnen. Ein weiteres Problem dabei: Etwa 25 % der AMD-Erkrankungen werden im Rahmen der augenärztlichen Grundversorgung nicht erkannt.1,2 ZEISS kann ihnen helfen: Mit Advanced RPE Analysis und AngioPlex® – dem Toolkit für die AMD-Diagnose und das Management von Patientinnen und Patienten mit altersabhängiger Makuladegeneration und geografischer Atrophie. Erfahren Sie hier, wie Sie beide Funktionen kombinieren und zum Wohle Ihrer Patientinnen und Patienten nutzen können.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.100.100.80,0,560,480.file/196-million.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.360.360.80,0,560,480.file/196-million.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png"})
Im Jahr 2020 litten schätzungsweise 196 Millionen Menschen an AMD.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.100.100.23,0,428,405.file/affect-central-vision_lrg.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.360.360.23,0,428,405.file/affect-central-vision_lrg.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg"})
Weitere 92 Millionen Menschen sind gefährdet, an AMD zu erkranken und schwere Beeinträchtigungen des zentralen Sehens zu entwickeln oder sogar zu erblinden.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.100.100.80,0,560,480.file/60-plus.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.360.360.80,0,560,480.file/60-plus.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png"})
Das Risiko für die Erkrankung an AMD ist besonders für Menschen ab 60 Jahren erhöht.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.100.100.23,0,428,405.file/risk-factors_lrg.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.360.360.23,0,428,405.file/risk-factors_lrg.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg"})
Zu den Risikofaktoren der altersabhängigen Makuladegeneration gehören u. a. Rauchen, ungesunde Ernährung, zu wenig Bewegung, Sonnenstrahlung und familiäre Prädisposition.
Eine neue Ära für die Behandlung der geografischen Atrophie
Die Rolle der OCT
![Advanced RPE Analysis]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.100.56.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.360.203.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.768.432.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1024.576.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg"} "Advanced RPE Analysis")
Advanced RPE Analysis
Quantitative Messung und Vergleich mit vorangehenden Untersuchungen
Die Advanced RPE Analysis für ZEISS CIRRUS OCT wurde speziell dafür entwickelt, Ärztinnen und Ärzten bei der Versorgung aller Formen der trockenen AMD zu unterstützen.
![AngioPlex]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.100.56.0,130,1341,886.file/article_2_figure_2-octa_report.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.360.203.0,130,1341,886.file/article_2_figure_2-octa_report.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.768.432.0,130,1341,886.file/article_2_figure_2-octa_report.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1024.576.0,130,1341,886.file/article_2_figure_2-octa_report.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1280.720.0,130,1341,886.file/article_2_figure_2-octa_report.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1341.754.0,130,1341,886.file/article_2_figure_2-octa_report.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1341.754.0,130,1341,886.file/article_2_figure_2-octa_report.png"} "AngioPlex")
AngioPlex
Die Bedeutung einer frühzeitigen Progressionserkennung
Systeme für die OCT-Angiografie (OCTA) wie ZEISS CIRRUS AngioPlex® verbessern kontinuierlich die Möglichkeiten der ophthalmologischen Bildgebung und ermöglichen damit eine bessere Versorgung betroffener Patientinnen und Patienten.
![Ein Modell für die gemeinschaftliche Versorgung]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.100.56.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.360.203.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.768.432.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1024.576.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1280.720.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1440.810.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1920.1080.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png"} "Ein Modell für die gemeinschaftliche Versorgung")
Ein Modell für die gemeinschaftliche Versorgung
Bessere Ergebnisse für Ihre Patienten und Patientinnen
ZEISS CIRRUS OCT mit Advanced RPE Analysis und AngioPlex® kann die Datengrundlage liefern, mit deren Hilfe Optometristen und Ophthalmologen alle Formen der altersabhängigen Makuladegeneration diagnostizieren und überwachen können.
Downloads
![Vorschaubild von Advanced RPE Retina Workplace Flyer EN]({"max":"https://asset-downloads.zeiss.com/catalogs/preview/med2/2eb5679b-46fb-45a4-b601-a040c641d7c2/ZEISS-AdvancedRPE-RetinaWorkplace-en-INT_31_012_0051I_612936_0.pdf.jpg"} "Download Advanced RPE Retina Workplace Flyer EN")
![Vorschaubild von CIRRUS Advanced RPE Analysis EN]({"max":"https://asset-downloads.zeiss.com/catalogs/preview/med2/0e264e73-9895-46c3-9a75-b653bc0be55e/AdvRPEanalysis-AppNote_en-INT_31_012_0050I_615202_0.pdf.jpg"} "Download CIRRUS Advanced RPE Analysis EN")
Kontaktieren Sie uns!
Verfügbare Services
-
1
Wong WL et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health 2.2 (2014): e106-e116
-
2
Neely DC, Bray KJ, Huisingh CE, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol 2017; 135(6): 570–5